The esketamine MDD study reports statistically significant acute symptom reduction while flagging durability/relapse as a labeling concern.

A new study on esketamine — a fast-acting drug already approved for depression — is expected to show it works well at cutting depression symptoms quickly. But the results will likely also highlight a catch: symptoms can come back, and it's unclear how to keep people well long-term. This split result — 'yes it works, but...' — matters because it shapes what doctors are allowed to say and prescribe.

Esketamine has an established regulatory track; acute efficacy wins are reliable, but maintenance dosing and relapse are where labels get contested. Split outcome is the specific, testable claim.